Research Progress of Anti-PD-1/PD-L1 Therapy for Non-small Cell Lung Cancer
with EGFR Mutation.
10.3779/j.issn.1009-3419.2022.101.44
- Author:
Yue ZHU
1
;
Zhaoxia DAI
1
Author Information
1. The Second Affiliated Hospital of Dalian Medical University, Dalian 116021, China.
- Publication Type:Journal Article
- Keywords:
Immune therapy;
Lung neoplasms;
Tumor microenvironment
- MeSH:
Humans;
Carcinoma, Non-Small-Cell Lung/pathology*;
B7-H1 Antigen/metabolism*;
Lung Neoplasms/pathology*;
Immune Checkpoint Inhibitors;
Ligands;
Mutation;
ErbB Receptors/metabolism*;
Protein Kinase Inhibitors/therapeutic use*
- From:
Chinese Journal of Lung Cancer
2022;25(10):742-749
- CountryChina
- Language:Chinese
-
Abstract:
The use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is the first line treatment for EGFR-mutant advanced non-small cell lung cancer (NSCLC), but drug resistance will be acquired within 1-2 years, and the following treatment efficacy is poor. The invention of programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors has dramatically changed the situation of tumor treatment. PD-1/PD-L1 inhibitors are less effective in patients with NSCLC harboring EGFR mutation. It is a challenge to make patients with EGFR-mutated advanced NSCLC benefit from anti-PD-1/PD-L1 therapy. In this paper, the research progress on the impact of EGFR mutation on the immune status of NSCLC and related clinical studies in recent 5 years are reviewed.
.
